After multiple setbacks, Bristol Myers scuttles Opdivo program for brain tumor patients after failing to prolong lives
Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Despite holding a slim hope Opdivo would turn around its chances, Bristol is ready to call it quits for now.
Bristol’s combo of Opdivo on top of standard-of-care temozolomide plus radiation couldn’t beat placebo in extending overall survival in patients with newly diagnosed MGMT-positive glioblastoma multiforme who previously had their tumor surgically removed, the company said Wednesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.